Lung Diseases, Interstitial
18 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Anti Thymocyte Globulin + GM-CSF + Total Body Irradiation + ALEMTUZUMAB + RITUXIMAB + HUMAN IMMUNOGLOBULIN G + Cyclophosphamide + THIOTEPA + Mesna for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Azithromycin 250 mg x3/week (3 tablets/week) + Hydroxychloroquine + Prednisone for lung diseases, interstitial | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BC006 for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Belimumab for lung diseases, interstitial | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Belumosudil 200 mg QD for pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bersiporocin for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CAL101 for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Caspofungin for lung diseases, interstitial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine 0.5 mg for pulmonary fibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| COVID-19 CONVALESCENT PLASMA for lung diseases, interstitial | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dry Powder Inhaler + inhaled mosliciguat for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HB0056 for idiopathic pulmonary fibrosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HSK44459 for idiopathic pulmonary fibrosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rentosertib for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ROC-101 for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy + Volume Modulated Arc Therapy + NIVOLUMAB + IPILIMUMAB for lung diseases, interstitial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Taladegib for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tulisokibart for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |